Revance Therapeutics Inc (RVNC) was one of the Russell 2000's biggest losers for Thursday February 18 as the stock slid 6.43% to $18.33, a loss of $-1.26 per share. Starting at an opening price of $19.62 a share, the stock traded between $18.09 and $19.70 over the course of the trading day. Volume was 180,208 shares over 1,938 trades, against an average daily volume of 454,412 shares and a total float of 28.06 million.
The losses send Revance Therapeutics Inc down to a market cap of $514.38 million. In the last year, Revance Therapeutics Inc has traded between $42.41 and $14.10, and its 50-day SMA is currently $27.84 and 200-day SMA is $30.09.
Revance Therapeutics Inc is a clinical stage specialty biopharmaceutical company, engaged in the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications.
Revance Therapeutics Inc is based out of Newark, CA and has some 102 employees. Its CEO is L. Daniel Browne.
For a complete fundamental analysis analysis of Revance Therapeutics Inc, check out Equities.com’s Stock Valuation Analysis report for RVNC. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.
The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.
Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.
For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.
All data provided by QuoteMedia and was accurate as of 4:30PM ET.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer